Authors
Alexa B Schrock, Garrett M Frampton, James Suh, Zachary R Chalmers, Mark Rosenzweig, Rachel L Erlich, Balazs Halmos, Jonathan Goldman, Patrick Forde, Kurt Leuenberger, Nir Peled, Gregory P Kalemkerian, Jeffrey S Ross, Philip J Stephens, Vincent A Miller, Siraj M Ali, Sai-Hong Ignatius Ou
Publication date
2016/9/1
Journal
Journal of Thoracic Oncology
Volume
11
Issue
9
Pages
1493-1502
Publisher
Elsevier
Description
Background
The hepatocyte growth factor receptor gene (MET) exon 14 skipping (METex14) has recently been described a potential driver alteration in lung cancer targetable by mesenchymal-to-epithelial transition factor (MET) tyrosine kinase inhibitors (TKIs).
Methods
Well-validated hybrid capture–based comprehensive genomic profiling was performed at the request of individual treating physicians.
Results
Of 11,205 lung cancers profiled by comprehensive genomic profiling, 298 (2.7%) carcinomas harbored alterations predicted to cause METex14, including adenosquamous (8.2%), sarcomatoid (7.7%), histologic subtype not otherwise specified (3.0%), adenocarcinoma (2.9%), squamous cell (2.1%), large cell (0.8%), and SCLC (0.2%). Acinar features were present in 24% of the METex14 samples. Six cases (2%) harbored MET Y1003X mutations affecting binding of the MET-negative regulator, E3 ubiquitin …
Scholar articles
AB Schrock, GM Frampton, J Suh, ZR Chalmers… - Journal of Thoracic Oncology, 2016